FlowMo

FlowMo is a digital health company focused on cardiac care solutions, leveraging AI to detect, predict, and prevent disease.

Reviewed by 7wData
Share Email

On this page

Profile

FlowMo provides AI-powered cardiac monitoring solutions to detect and predict heart disease.

FlowMo is a digital health company focused on cardiac care solutions, leveraging AI to detect, predict, and prevent disease. Founded in the early 2020s, the company has grown to become a notable player in the ambulatory ECG monitoring space, with its flagship Zio platform. FlowMo's revenue for Q1 2026 was $199.4 million, a 25.7% increase year-over-year, driven by sustained demand for its Zio services.

The company reported a net loss of $13.9 million, an improvement from $30.7 million in Q1 2025, reflecting operational efficiencies and scale benefits. FlowMo's gross margin expanded to 70.9%, up 210 basis points, supported by higher volumes and cost management. The company holds $549.6 million in cash and marketable securities as of March 2026.

FlowMo's recent operational highlights include presentations at major cardiology conferences and the launch of a digital education platform. The company has raised its 2026 revenue guidance to $875-$885 million, targeting an adjusted EBITDA margin of 12-13%. FlowMo's growth is underpinned by diversification across cardiology, primary care, and international markets, alongside partnerships and AI-enabled capabilities.

Track FlowMo and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Cardiology clinics and hospitals
  • Primary care providers
  • Employers and wellness programs
  • International healthcare systems
  • Clinical research organizations

Strengths and what to watch

Strengths

  • Strong revenue growth (25.7% YoY in Q1 2026) driven by durable demand for Zio platform
  • Expanding gross margins (70.9% in Q1 2026) due to operational efficiencies and scale
  • Diversified growth channels, including international markets and innovative partnerships

Watch for

  • Net losses persist ($13.9 million in Q1 2026), though improving year-over-year
  • Dependence on Zio platform for majority of revenue, with limited product diversification
  • Regulatory and reimbursement risks in international markets

Key Information

Founded
2020

Frequently Asked Questions

What does FlowMo do?

FlowMo provides AI-powered cardiac monitoring solutions to detect and predict heart disease. Their flagship Zio platform is widely used in ambulatory ECG monitoring, helping cardiology clinics, hospitals, and primary care providers improve patient outcomes through advanced AI-enabled capabilities.

How has FlowMo performed financially?

FlowMo reported $199.4 million in Q1 2026 revenue, a 25.7% year-over-year increase. Despite a net loss of $13.9 million, the company improved operational efficiencies, expanded gross margins to 70.9%, and raised its 2026 revenue guidance to $875-$885 million.

What is FlowMo's Zio platform?

FlowMo's Zio platform is an AI-powered ambulatory ECG monitoring solution designed to detect and predict heart disease. It is a key driver of the company's revenue growth, widely adopted by cardiology clinics, hospitals, and primary care providers for its advanced capabilities.

Who uses FlowMo's solutions?

FlowMo's solutions are used by cardiology clinics, hospitals, primary care providers, employers, wellness programs, international healthcare systems, and clinical research organizations. Their AI-powered cardiac monitoring tools cater to diverse healthcare needs across multiple segments.

What are FlowMo's growth strategies?

FlowMo focuses on diversification across cardiology, primary care, and international markets, alongside innovative partnerships. Their growth is supported by AI-enabled capabilities, operational efficiencies, and expanding gross margins, targeting an adjusted EBITDA margin of 12-13% in 2026.

What challenges does FlowMo face?

FlowMo faces challenges like net losses, dependence on the Zio platform for revenue, and regulatory risks in international markets. Despite these, the company is improving operational efficiencies and diversifying its growth channels to mitigate risks.

Sources

  1. investors.irhythmtech.com — Q1 2026 financial results and operational highlights
  2. www.bloomberg.com — Context on tech sector layoffs and economic conditions
  3. techcrunch.com — Broader AI industry trends
  4. userevidence.com — Market trends in customer evidence and B2B sales